METlung_3A | R Documentation |
Kaplan-Meier digitized data from METlung, figure 3A (PMID 27937096). A reported sample size of 499 for a primary endpoint of OS in lung cancer.
METlung_3A
A data frame of 499 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (onaturzumab_erlotinib, placebo_erlotinib) | |
Spigel DR, Edelman MJ, O’Byrne K, et al. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. J Clin Oncol 2017; 35: 412–20.
summary(METlung_3A)
kmplot(METlung_3A)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.